Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies
- PMID: 38250027
- PMCID: PMC10796792
- DOI: 10.3389/fcvm.2023.1257335
Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies
Abstract
Introduction: The influence of sex on the prognosis of heart failure with preserved or intermediate ejection fraction (HFpEF and HFmrEF) remains uncertain. This study aimed to investigate whether sex differences impact the prognosis of patients diagnosed with HFpEF and HFmrEF.
Methods: A comprehensive search across three databases (PubMed, the Cochrane Library, and Embase) was conducted to identify sex-related prognostic cohort studies focusing on HFpEF and HFmrEF. Risk estimates were synthesized using the random effects model. The analysis included 14 cohorts comprising 41,508 HFpEF patients (44.65% males) and 10,692 HFmrEF patients (61.79% males).
Results: Among HFpEF patients, men exhibited significantly higher rates of all-cause mortality (13 studies; hazard ratio (HR): 1.24, 95% confidence interval (CI): 1.15 to 1.33)) and cardiovascular disease mortality (5 studies; HR: 1.22, 95% CI: 1.14 to 1.31) compared to women. However, no significant difference was observed in HF admissions. For HFmrEF patients, men displayed notably higher all-cause mortality (HR: 1.21, 95% CI: 1.12 to 1.31) but no significant differences in cardiovascular mortality or HF admissions.
Discussion: These findings suggest that male patients diagnosed with HFpEF and HFmrEF may face a more unfavorable prognosis in terms of all-cause mortality. Variations were noted in cardiovascular mortality and HF admissions, indicating potential complexities in sex-related prognostic factors within these heart failure categories. In summary, male patients with HFpEF and HFmrEF may have a more unfavorable prognosis.
Keywords: HF; HFmrEF; HFpEF; meta-analysis; prognosis; sex.
© 2024 Deng, Zhang, Ling, Hu, Song, Xu, Liu, Wu, Mei, Chen, Zhao and Liu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10796792/bin/fcvm-10-1257335-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10796792/bin/fcvm-10-1257335-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10796792/bin/fcvm-10-1257335-g003.gif)
Similar articles
-
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.Eur J Med Res. 2022 Dec 29;27(1):314. doi: 10.1186/s40001-022-00945-z. Eur J Med Res. 2022. PMID: 36581880 Free PMC article. Review.
-
Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis.Clin Cardiol. 2022 Jan;45(1):5-17. doi: 10.1002/clc.23754. Epub 2022 Jan 18. Clin Cardiol. 2022. PMID: 35043472 Free PMC article.
-
Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.JACC Heart Fail. 2019 Jun;7(6):505-515. doi: 10.1016/j.jchf.2019.03.011. JACC Heart Fail. 2019. PMID: 31146874
-
A comprehensive population-based characterization of heart failure with mid-range ejection fraction.Eur J Heart Fail. 2017 Dec;19(12):1624-1634. doi: 10.1002/ejhf.945. Epub 2017 Sep 25. Eur J Heart Fail. 2017. PMID: 28948683
-
Similarities and Differences Between HFmrEF and HFpEF.Front Cardiovasc Med. 2021 Sep 20;8:678614. doi: 10.3389/fcvm.2021.678614. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34616777 Free PMC article. Review.
References
-
- GBD Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. (2018) 392:1789–858. 10.1016/S0140-6736(18)32279-7 - DOI - PMC - PubMed
-
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Card Fail. (2017) 23:628–51. 10.1016/j.cardfail.2017.04.014 - DOI - PubMed
-
- O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation. (2007) 115:3111–20. 10.1161/CIRCULATIONAHA.106.673442 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous